ORLYNVAH commercial launch and share offering
On October 16, 2025, Iterum Therapeutics announced a new $20 million "at-the-market" share offering to be conducted under an existing sales agreement.
As part of a business update provided 11 hours earlier, the company shared details on the ongoing commercial launch of ORLYNVAH (oral sulopenem) in the U.S. community market. Iterum Therapeutics expects modest sales for ORLYNVAH™ during the initial commercialization period in 2025.
The FDA-approved antibiotic is the first oral penem antibiotic in the U.S. and is intended to treat uncomplicated urinary tract infections (uUTIs) in adult women with limited alternative oral treatment options.
On October 16, 2025, Iterum Therapeutics announced a new $20 million "at-the-market" share offering to be conducted under an existing sales agreement.
As part of a business update provided 11 hours earlier, the company shared details on the ongoing commercial launch of ORLYNVAH (oral sulopenem) in the U.S. community market. Iterum Therapeutics expects modest sales for ORLYNVAH™ during the initial commercialization period in 2025.
The FDA-approved antibiotic is the first oral penem antibiotic in the U.S. and is intended to treat uncomplicated urinary tract infections (uUTIs) in adult women with limited alternative oral treatment options.
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.
Declinazione di responsabilità
Le informazioni e le pubblicazioni non sono intese come, e non costituiscono, consulenza o raccomandazioni finanziarie, di investimento, di trading o di altro tipo fornite o approvate da TradingView. Per ulteriori informazioni, consultare i Termini di utilizzo.